This prospective cohort study examines the association between hormone replacement therapy use after oophorectomy and risk of breast cancer among women with a BRCA1 mutation.
This population-based cohort study examines the effect of multiple-gene sequencing on the experiences and treatment outcomes of patients with breast cancer.
This analysis examines the characteristics of radiotherapy interventional trials compared with other oncological interventional trials reported in ClinicalTrials.gov from 2007 through 2017.
This cost-effectiveness analysis of data from the FLAURA randomized clinical trial evaluates the incremental cost-effectiveness ratio expressed as cost per quality-adjusted life-year of osimertinib as a first-line treatment for patients with EGFR-mutated advanced non–small cell lung cancer in the United States and Brazil.
This whole-genome transcriptomic analysis uses next-generation sequencing to characterize the immune profile of premalignant lesions from a cohort of patients with Lynch syndrome.
This cross-sectional study uses demographic data, FDA drug-approval information, drug labels, and other published sources to estimate the percentage of US patients with cancer who were eligible for and benefited from genome-driven oncology from January 2006 through January 2018.
This Korean national cohort study investigates whether the development of cancer is associated with increasing risk of subsequent diabetes.
This cohort study determines whether circulating tumor cell status is associated with radiotherapeutic benefit in terms of overall, local recurrence-free, and disease-free survival in patients with early-stage breast cancer.
This cohort study assesses the speed with which inhibitors of programmed cell death 1 protein reached eligible patients in practice and compares the ages of patients treated in clinical practice with the ages of those treated in pivotal clinical trials.
This analysis of data from a phase 1/2 study evaluates potential cases of isocitrate dehydrogenase differentiation syndrome among patients treated with enasidenib for relapsed/refractory acute myeloid leukemia.
This comparative study uses data from the US Food and Drug Administration Adverse Event Reporting System database to investigate the association between treatment with nivolumab in combination with epidermal growth factor receptor-tyrosine kinase inhibitors and interstitial pneumonitis in patients with non–small cell lung cancer.
This study uses data from the National Cancer Database to estimate utilization rates and factors associated with chemotherapy and radiation therapy delivery for limited-stage small cell lung cancer.
This study investigates the association between immunotherapy and symptomatic radiation necrosis in patients with melanoma, non–small-cell lung cancer, or renal cell carcinoma and newly diagnosed brain metastases treated with stereotactic radiation therapy.
This review of medical literature examines the criteria for diagnosis of noninvasive follicular thyroid neoplasm with papillarylike nuclear features.
This cross-sectional survey study investigates how older US adults want their health care clinicians to frame discussions about stopping routine cancer screening.
This population-based study investigates the survival and causes of death in patients with pancreatic adenocarcinoma to 21 years after diagnosis.
This population-based, case-control study analyzes the potential barriers to cancer care resources in rural Honduras in a cohort of patients with gastric cancer.
This Insights discusses management strategies for relapsed and refractory Hodgkin lymphoma using the most recent therapeutic options.
A woman in her 30s with metastatic soft tissue sarcoma being treated with nivolumab presented with diffuse macular cutaneous eruption and pruritus. What is your diagnosis?
This Viewpoint examines ethical concerns with respect to biopsy procedures performed in clinical trials and proposes a set of recommendations for biopsy results reporting.
This Viewpoint examines the challenges facing US adolescents and young adult patients with cancer and access to insurance coverage since the 2010 Patient Protection and Affordable Care Act.
This Viewpoint describes the increasing imbalance in health care costs and health coverage in oncology and suggests a strategy to develop a comprehensive cost of care task force.
This article describes the experience of a physician in the Netherlands who has performed euthanasia at the request of a patient.
Create a personal account or sign in to: